The first case of Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in December 2019. This virus belongs to the beta-coronavirus group that contains a single stranded RNA with a nucleoprotein within a capsid. SARS-CoV-2 shares 80% nucleotide identity to SARS-CoV. The virus is disseminated by its binding to the ACE2 receptors on bronchial epithelial cells. The diagnosis of COVID-19 is based on a laboratory-based reverse transcription polymerase chain reaction (RT-PCR) test together with chest computed tomography imaging. To date, no antiviral therapy has been approved, and many aspects of the COVID-19 are unknown. In this review, we will focus on the recent information on genetics and pathogenesis of COVID-19 as well as its clinical presentation and potential treatments.
【저자키워드】 SARS-CoV-2, Betacoronavirus, remidisvir, spike surface glycoprotein, 【초록키워드】 COVID-19, antiviral therapy, Coronavirus disease 2019, coronavirus, SARS-CoV, ACE2 receptor, RT-PCR, virus, genetics, RNA, Chest computed tomography, reverse transcription, information, binding, nucleotide, beta-coronavirus, identity, acute respiratory syndrome, potential treatments, pathogenesis of COVID-19, bronchial epithelial cells, polymerase chain, caused, reported, approved, diagnosis of COVID-19, 【제목키워드】 pathogenic,